Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Elevance Health Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Medical claims payable	15,746)	16,111)	15,596)	13,518)	11,359)
Other policyholder liabilities	4,204)	5,600)	5,933)	5,521)	4,590)
Unearned income	1,508)	1,402)	1,112)	1,153)	1,259)
Accounts payable and accrued expenses	6,927)	6,910)	5,607)	4,970)	5,493)
Short-term borrowings	365)	225)	265)	275)	—)
Current portion of long-term debt	1,649)	1,649)	1,500)	1,599)	700)
Other current liabilities	10,029)	9,894)	9,683)	7,849)	6,052)
Liabilities held for sale	153)	—)	—)	—)	—)
Current liabilities	40,581)	41,791)	39,696)	34,885)	29,453)
Long-term debt, less current portion	29,218)	23,246)	22,349)	21,157)	19,335)
Reserves for future policy benefits	190)	778)	737)	802)	794)
Deferred tax liabilities, net	2,148)	1,970)	2,034)	2,805)	2,019)
Other noncurrent liabilities	3,326)	1,738)	1,562)	1,683)	1,815)
Noncurrent liabilities	34,882)	27,732)	26,682)	26,447)	23,963)
Total liabilities	75,463)	69,523)	66,378)	61,332)	53,416)
Preferred stock, without par value; shares issued and outstanding: none	—)	—)	—)	—)	—)
Common stock, par value $0.01	2)	2)	2)	2)	3)
Additional paid-in capital	8,911)	8,868)	9,084)	9,148)	9,244)
Retained earnings	33,549)	31,749)	29,724)	27,088)	23,802)
Accumulated other comprehensive income (loss)	(1,147)	(1,313)	(2,503)	(178)	150)
Shareholders’ equity	41,315)	39,306)	36,307)	36,060)	33,199)
Noncontrolling interests	111)	99)	87)	68)	—)
Total equity	41,426)	39,405)	36,394)	36,128)	33,199)
Total liabilities and equity	116,889)	108,928)	102,772)	97,460)	86,615)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Liabilities Trends: The total liabilities exhibit a consistent upward trend from US$53,416 million in 2020 to US$75,463 million in 2024. This increase is primarily driven by growth in both current and noncurrent liabilities.; Medical claims payable increased from US$11,359 million in 2020 to a peak of US$16,111 million in 2023, before a slight decrease to US$15,746 million in 2024, indicating a rising trend in health-related obligations over the period with a minor decline in the final year.; Other policyholder liabilities initially rose from US$4,590 million in 2020 to US$5,933 million in 2022, followed by a notable decline to US$4,204 million in 2024, suggesting potential changes in policyholder obligations or risk mitigation.; Unearned income diminished slightly from US$1,259 million in 2020 to US$1,112 million in 2022 but recovered to US$1,508 million by 2024, possibly reflecting changes in revenue recognition or deferred premiums.; Accounts payable and accrued expenses displayed variability, decreasing to US$4,970 million in 2021 but increasing thereafter to US$6,927 million in 2024, indicating fluctuating short-term obligations.; Short-term borrowings were non-existent in 2020, appeared at US$275 million in 2021, and fluctuated modestly, ending at US$365 million in 2024, signifying limited reliance on short-term debt.; The current portion of long-term debt increased substantially from US$700 million in 2020 to US$1,649 million by 2023 and remained stable in 2024, reflecting higher near-term debt repayments.; Other current liabilities showed a strong increase from US$6,052 million in 2020 to US$10,029 million in 2024, indicating growing short-term obligations not categorized elsewhere.; The current liabilities aggregate rose steadily from US$29,453 million in 2020 to US$40,581 million in 2024, signifying elevated short-term financial commitments.; Long-term debt, less the current portion, increased from US$19,335 million in 2020 to US$29,218 million in 2024, demonstrating a strong rise in longer-term borrowings.; Reserves for future policy benefits decreased sharply, dropping from US$794 million in 2020 to US$190 million in 2024, which may reflect changes in actuarial assumptions or claims experience.; Deferred tax liabilities showed no consistent trend, fluctuating between US$1,970 million and US$2,805 million, standing at US$2,148 million in 2024.; Other noncurrent liabilities declined initially but rose significantly to US$3,326 million in 2024 from US$1,815 million in 2020, suggesting increase in other long-term obligations.; Reflecting these changes, total noncurrent liabilities increased from US$23,963 million in 2020 to US$34,882 million in 2024.
Equity Trends: Common stock remained virtually unchanged at US$2-3 million throughout the period, indicating no significant changes in issued shares.; Additional paid-in capital showed a slight decline from US$9,244 million in 2020 to US$8,911 million in 2024, reflecting modest adjustments in capital contributions.; Retained earnings increased steadily from US$23,802 million in 2020 to US$33,549 million in 2024, suggesting sustained profitability and earnings retention.; Accumulated other comprehensive income (loss) transitioned from a positive US$150 million in 2020 to negative values thereafter, reaching a loss of US$1,147 million in 2024, reflecting adverse changes in unrealized gains or losses.; Shareholders’ equity increased from US$33,199 million in 2020 to US$41,315 million in 2024, indicating growth in net assets.; Noncontrolling interests appeared from 2021 onward, increasing gradually to US$111 million by 2024, representing minor outside ownership stakes.; Total equity, combining shareholders’ equity and noncontrolling interests, grew from US$33,199 million in 2020 to US$41,426 million in 2024.
Overall Financial Position: Total liabilities and equity rose steadily from US$86,615 million in 2020 to US$116,889 million in 2024, signaling overall growth in the balance sheet size.; The company's financial structure shows increasing leverage as liabilities grow at a faster pace than equity, particularly through rises in long-term debt and current liabilities.; The decline in reserves for future policy benefits accompanied by stable or increasing liabilities may warrant further review of risk exposures and adequacy of reserves.

Download chart

Elevance Health Inc. (NYSE:ELV)

Balance Sheet: Liabilities and Stockholders’ Equity